S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

ADAG Adagene Inc

1.7795

0.00 (0.00%)

Pre Market

Last Updated: 03:02:24

Delayed by 15 minutes

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Adagene (NASDAQ:ADAG)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Adagene Charts.

Adagene (NASDAQ:ADAG)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Adagene Charts.

Adagene Inc News

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Monday 3 February 2025 (4 days ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 27 January 2025 (2 weeks ago) • Edgar (US Regulatory)

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]
Thursday 7 November 2024 (3 months ago) • Edgar (US Regulatory)

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]
Thursday 7 November 2024 (3 months ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Thursday 7 November 2024 (3 months ago) • Edgar (US Regulatory)

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Soc
Thursday 7 November 2024 (3 months ago) • GlobeNewswire Inc.

Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Wednesday 9 October 2024 (4 months ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 16 September 2024 (5 months ago) • Edgar (US Regulatory)

Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC
Monday 16 September 2024 (5 months ago) • GlobeNewswire Inc.

Adagene to Participate in Investor Conferences in September
Thursday 29 August 2024 (5 months ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Thursday 25 July 2024 (6 months ago) • Edgar (US Regulatory)

Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update
Thursday 25 July 2024 (6 months ago) • GlobeNewswire Inc.

More Adagene Inc News Articles

Bell Buckle (PK)

Health Advance (PK)

MineralRite (PK)

Decentral Life (PK)

TheGlobe com (PK)

Fannie Mae (QB)

Hannover House (PK)

Voip Pal Com (QB)

Tonix Pharmaceuticals

TransCode Therapeutics

Adia Nutrition (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions